{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:41:37Z","timestamp":1760186497066,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.hoc.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T07:27:27Z","timestamp":1459409247000},"page":"679-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange"],"prefix":"10.1016","volume":"30","author":[{"given":"Tahir","family":"Mehmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.01.009_bib1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.01.009_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. The sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.hoc.2016.01.009_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.hoc.2016.01.009_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. The Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.01.009_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","article-title":"High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome","volume":"82","author":"Coppo","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.hoc.2016.01.009_bib7","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jca.20017","article-title":"Frequency and significance of schistocytes in TTP\/HUS patients at the discontinuation of plasma exchange therapy","volume":"19","author":"Egan","year":"2004","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.hoc.2016.01.009_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z","article-title":"US TTP Apheresis Study Group. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange","volume":"13","author":"Bandarenko","year":"1998","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.hoc.2016.01.009_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2008.07292.x","article-title":"Methylene blue-photoactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study","volume":"143","author":"del Rio-Garma","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1423-0410.2007.00940.x","article-title":"Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura","volume":"93","author":"Scully","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.hoc.2016.01.009_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.hoc.2016.01.009_bib14","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib15","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2011.08636.x","article-title":"Human immunodeficiency virus associated thrombotic thrombocytopenic purpura\u2014favorable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy","volume":"153","author":"Hart","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2013.11.004","article-title":"Thrombotic microangiopathies","volume":"43","author":"Rosove","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.hoc.2016.01.009_bib20","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0140-6736(11)61145-8","article-title":"Management of an acute outbreak of diarrhea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study","volume":"378","author":"Colic","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.01.009_bib21","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hoc.2016.01.009_bib22","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic-uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2016.01.009_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-008-0935-6","article-title":"Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)","volume":"23","author":"Scheiring","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.hoc.2016.01.009_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumonia associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.hoc.2016.01.009_bib25","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.hoc.2016.01.009_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience","volume":"151","author":"Waters","year":"2007","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.hoc.2016.01.009_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620715577613","article-title":"Advances and challenges in the management of complement-mediated thrombotic microangiopathies","volume":"6","author":"Davin","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib28","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood-2013-11-516237","article-title":"How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/bmt.2009.233","article-title":"Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange","volume":"45","author":"Kennedy","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.01.009_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","article-title":"Thrombotic microangiopathy in haematopoietic stem cell transplantation diagnosis and treatment","volume":"69","author":"Choi","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.hoc.2016.01.009_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.01.009_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2016.01.009_bib33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessel, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2016.01.009_bib35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2016.01.009_bib36","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.hoc.2016.01.009_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib38","first-page":"292","article-title":"Is thrombotic microangiopathy a paraneoplastic phenomenon? Case report and review of the literature","volume":"4","author":"Houston","year":"2014","journal-title":"NDT Plus"},{"key":"10.1016\/j.hoc.2016.01.009_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2016.01.009_bib40","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/fon.14.113","article-title":"Metastatic cancer-related thrombotic microangiopathies: a cohort study","volume":"10","author":"Ducos","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2016.01.009_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.12907","article-title":"Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?","volume":"166","author":"Favre","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.hoc.2016.01.009_bib43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systemic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.01.009_bib44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2016.01.009_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0032-1328886","article-title":"Drug-associated thrombotic microangiopathies","volume":"38","author":"Kreuter","year":"2012","journal-title":"Semin Thromb Hemost"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:03:30Z","timestamp":1760184210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0889858816000101"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.01.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}